drugset
drugset / Trial / NCT02375633

Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients

NCT02375633 ↗

Phase 3 Completed 166 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients.

Timeline

Start
2014-04
Primary completion
2014-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject DW-330SR2 Unknown 45 mg —
Comparator Pelubiprofen Small molecule 30 mg —

Indications

chronic pain syndrome